Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Cited by (744)

Items 101–200 of 744

1. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
   Navonil De Sarkar, Robert D. Patton, Anna-Lisa Doebley, Brian P. Hanratty, Adam J. Kreitzman, Jay F. Sarthy, Minjeong Ko, Mohamed Adil, Sandipan Brahma, Michael P. Meers et al. · 2022 · Cancer Discovery
2. Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
   Takuma Uo, Cynthia C.T. Sprenger, Stephen R. Plymate · 2020 · Frontiers in Oncology
3. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer
   Yuzhen Liu, Jessie L. Horn, Kalyan Banda, Asha Z. Goodman, Yiting Lim, Sujata Jana, Sonali Arora, Alexandre A. Germanos, Lexiaochuan Wen, William R. Hardin et al. · 2019 · Science Translational Medicine
4. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
   Justin H. Hwang, Ji-Heui Seo, Michael L. Beshiri, Stephanie A. M. Wankowicz, David Liu, Alexander T. M. Cheung, Ji Li, Xintao Qiu, Andrew Lee Hong, Ginevra Botta et al. · 2019 · Cell Reports
5. Multiplexed functional genomic analysis of 5’ untranslated region mutations across the spectrum of prostate cancer
   Yiting Lim, Sonali Arora, Samantha L. Schuster, Lukas Corey, Matthew Fitzgibbon, Cynthia L. Wladyka, Xiaoying Wu, Ilsa M. Coleman, Jeffrey J. Delrow, Eva Corey et al. · 2021 · Nature Communications
6. Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
   Chaping Cheng, Jinming Wang, Penghui Xu, Kai Zhang, Zhixiang Xin, Huifang Zhao, Zhongzhong Ji, Man Zhang, Deng Wang, Yuman He et al. · 2022 · Nature Cancer
7. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
   Florian Handle, Stefan Preković, Christine Helsen, Thomas Van den Broeck, Elien Smeets, Lisa Moris, Roy Eerlings, Sarah El Kharraz, Alfonso Urbanucci, Ian Geoffrey Mills et al. · 2019 · Scientific Reports
8. TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53 -Mutated Prostate Cancer
   Alexandra M. Blee, Yundong He, Yinhui Yang, Zhenqing Ye, Yuqian Yan, Yunqian Pan, Tao Ma, Joseph A. Dugdale, Emily Kuehn, Manish Kohli et al. · 2018 · Clinical Cancer Research
9. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
   N. G. R. Dayan Elshan, Matthew B. Rettig, Michael E. Jung · 2018 · Medicinal Research Reviews
10. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers
    John W. Phillips, Yang Pan, Brandon L. Tsai, Zhijie Xie, Levon Demirdjian, Wen Xiao, Harry Taegyun Yang, Yida Zhang, Chia Ho Lin, Donghui Cheng et al. · 2020 · Proceedings of the National Academy of Sciences
11. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
    Michael L. Mohler, Arunima Sikdar, Suriyan Ponnusamy, Dong‐Jin Hwang, Yali He, Duane D. Miller, Ramesh Narayanan · 2021 · International Journal of Molecular Sciences
12. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
    Gian Marco Franceschini, Orsetta Quaini, Kei Mizuno, Francesco Orlando, Yari Ciani, Sheng‐Yu Ku, Michael Sigouros, Emily C. Rothmann, Alicia Alonso, Matteo Benelli et al. · 2023 · Cancer Discovery
13. Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers via Modulation of Inflammation and Cell Signaling Molecules
    Saleh A. Almatroodi, Ahmad Almatroudi, Hajed Obaid Alharbi, Amjad Ali Khan, Arshad Husain Rahmani · 2024 · Molecules
14. Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
    Poornima Verma, Neha Shukla, Shivani Kumari, M.S. Ansari, Naveen Kumar Gautam, Girijesh Kumar Patel · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
15. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution
    Jarrell Imamura, Shinjini Ganguly, Andrew Muskara, Ross S. Liao, Jane Nguyen, Christopher Weight, Christopher Eing Wee, Shilpa Gupta, Omar Y. Mian · 2023 · Frontiers in Endocrinology
16. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
    Samir Zaidi, Jooyoung Park, Joseph Minhow Chan, Martine P. Roudier, Jimmy L. Zhao, Anuradha Gopalan, Kristine M. Wadosky, Radhika A. Patel, Erolcan Sayar, Wouter R. Karthaus et al. · 2024 · Proceedings of the National Academy of Sciences
17. Clinical considerations for the management of androgen indifferent prostate cancer
    Jacob E. Berchuck, Paul Vincent Viscuse, Himisha Beltran, Ana M. Aparicio · 2021 · Prostate Cancer and Prostatic Diseases
18. Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics
    Luiz Paulo Chaves, Camila Morais Melo, Fabiano Pinto Saggioro, Rodolfo Borges dos Reis, Jeremy Andrew Squire · 2021 · Genes
19. Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1
    Joshua W. Russo, Mannan Nouri, Steven P. Balk · 2019 · Cancer Discovery
20. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer
    Joshua W. Russo, Ce Gao, Swati Sharma Bhasin, Olga S. Voznesensky, Carla Calagua, Seiji Arai, Peter S. Nelson, Bruce Montgomery, Elahe A. Mostaghel, Eva Corey et al. · 2018 · Cancer Research
21. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer
    David R. Wise, Jeffrey A. Schneider, Joshua Armenia, Victor Adorno Febles, Bridget E. McLaughlin, Ryan Brennan, Katie L. Thoren, Wassim M. Abida, Karen Sandell Sfanos, Angelo Michael De Marzo et al. · 2020 · JCO Precision Oncology
22. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT
    Tao Shen, Wei Wang, Wolong Zhou, Ilsa M. Coleman, Qinbo Cai, Bingning Dong, Michael Ittmann, Chad J. Creighton, Yingnan Bian, Yan–Ling Meng et al. · 2021 · Journal of Clinical Investigation
23. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer
    Yasutaka Yamada, Varadha Balaji Venkadakrishnan, Kei Mizuno, Martin K. Bakht, Sheng‐Yu Ku, Maria Mica Garcia, Himisha Beltran · 2023 · Science Translational Medicine
24. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
    Thomas Christopher Westbrook, Xiangnan Guan, Eva S. Rodansky, Diana Lisbeth Flores, Chia-Jen Liu, Aaron M. Udager, Radhika A. Patel, Michael C. Haffner, Ya‐Mei Hu, Duanchen Sun et al. · 2022 · Nature Communications
25. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts
    Hung‐Ming Lam, Holly M. Nguyen, Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman, Roman Gulati, Bryce Lakely, Daniel Sondheim, Payel Chatterjee, Brett T. Marck et al. · 2019 · European Urology
26. Long-Chain Acyl-CoA Synthetase 4–Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway–Independent Prostate Cancer
    Yongjie Ma, Xiaohan Zhang, Omar Awad Alsaidan, Xiangkun Yang, Essilvo Sulejmani, Junyi Zha, Zanna M. Beharry, Hanwen Huang, Michael G. Bartlett, Zachary Lewis et al. · 2020 · Molecular Cancer Research
27. Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis
    Josef Leibold, Marcus A. Ruscetti, Zhen Cao, Yu-Jui Ho, Timour Baslan, Min Zou, Wassim M. Abida, Judith Feucht, Teng Han, Francisco M. Barriga et al. · 2020 · Cancer Discovery
28. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
    William Nathaniel Brennen, Yezi Zhu, Ilsa M. Coleman, Susan L. Dalrymple, Lizamma Antony, Radhika A. Patel, Brian P. Hanratty, Roshan V. Chikarmane, Alan Keith Meeker, S. Lilly Zheng et al. · 2021 · JCI Insight
29. Dissecting the role of cancer‐associated fibroblast‐derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single‐cell transcriptomic study
    Shaoquan Zheng, Jie‐Ying Liang, Yuhui Tang, Jindong Xie, Yutian Zou, Anli Yang, Nan Shao, Xiaying Kuang, Fei Ji, Xuefeng Liu et al. · 2023 · Clinical and Translational Medicine
30. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
    Avanish Mishra, Shih‐Bo Huang, Taronish D. Dubash, Risa Burr, Jon F., Ben S. Wittner, Quinn E. Cunneely, Victor R. Putaturo, Akansha Deshpande, Ezgi Antmen et al. · 2025 · Nature Communications
31. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells
    Lingling Fan, Songhui Xu, Fengbo Zhang, Xiaolu Cui, Ladan Fazli, Martin Edwin Gleave, David J. Clark, Austin J. Yang, Arif Hussain, Feyruz Virgilia Rassool et al. · 2020 · Cell Death and Disease
32. The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?
    Carole Luthold, Tarek Hallal, David P. Labbé, François Bordeleau · 2022 · Cancers
33. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer
    James G. Kench, Mahul B. Amin, Daniel Maurice Berney, Éva Compérat, Ian A. Cree, Anthony James Gill, Arndt Hartmann, Santosh G. Menon, Holger Moch, George Jabboure Netto et al. · 2022 · Histopathology
34. Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma
    Edmund C.P. Chedgy, Gillian Rae Vandekerkhove, Cameron Herberts, Matti Annala, Adam Donoghue, Michael Sigouros, Elie J. Ritch, Werner Jan Struss, Saki Konomura, Janet Liew et al. · 2018 · The Journal of Pathology
35. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
    Alexandra N. Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa M. Coleman, Jared M. Lucas, Arja Kaipainen, Holly M. Nguyen, Daniel Sondheim, Lisha G. Brown, Lawrence D. True, John K. Lee et al. · 2019 · Clinical Cancer Research
36. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer
    Rayzel Candida Fernandes, John Toubia, Scott L. Townley, Adrienne R. Hanson, B. Kate Dredge, Katherine A. Pillman, Andrew G. Bert, Jean M. Winter, Richard D Iggo, Rajdeep Das et al. · 2021 · Cell Reports
37. Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jiménez‐Vacas, Ana Padilha, Andreas S. Varkaris, Steven P. Balk, Johann Sebastian De Bono, Adam Sharp · 2021 · Cancers
38. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
    Zifeng Wang, Scott L. Townley, Songqi Zhang, Mingyu Liu, Mu‐Qing Li, Maryam Labaf, Susan C. Patalano, Kavita Venkataramani, Kellee Renee Siegfried, Jill A. Macoska et al. · 2024 · Nature Communications
39. Targeting RET Kinase in Neuroendocrine Prostate Cancer
    Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi E. Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li et al. · 2020 · Molecular Cancer Research
40. ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
    Yaru Xu, Yuqiu Yang, Zhaoning Wang, Martin Sjöström, Yuyin Jiang, Yitao Tang, Siyuan Cheng, Su Deng, Choushi Wang, Julisa Gonzalez et al. · 2024 · Cancer Discovery
41. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer
    Sheng‐Yu Ku, Yanqing Wang, Maria Mica Garcia, Yasutaka Yamada, Kei Mizuno, Mark D. Long, Spencer R. Rosario, Meenalakshmi Chinnam, Majd Al Assaad, Loredana Puca et al. · 2024 · Journal of Clinical Investigation
42. Targeting the androgen receptor and overcoming resistance in prostate cancer
    David Johnson Einstein, Seiji Arai, Steven P. Balk · 2019 · Current Opinion in Oncology
43. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma
    Sara Laudato, Ana M. Aparicio, Filippo G. Giancotti · 2019 · Trends in cancer
44. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
    Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman, Bryce Lakely, Nicholas J. Brady, John K. Lee, Holly M. Nguyen, Dapei Li, Brian P. Hanratty, Michael C. Haffner et al. · 2021 · Cancer Research
45. Immunogenomic Landscape of Neuroendocrine Prostate Cancer
    Bhavneet Bhinder, Alison Ferguson, Michael Sigouros, Manik Uppal, Ahmed G. Elsaeed, Rohan Bareja, Hussein H. Alnajar, Kenneth Wha Eng, Vincenza Conteduca, Andrea Sboner et al. · 2023 · Clinical Cancer Research
46. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer
    Chanping You, Man‐Hong Leung, W.H. Tsang, US Khoo, Ho Tsoi · 2022 · Biomolecules
47. Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
    Diana Cardoso Simão, Kevin Kayvan Zarrabi, José Leão Mendes, Ricardo da Luz, Jorge Alberto Garcia, William Kevin Kelly, Pedro Coelho Barata · 2023 · Cancers
48. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled
    Haley Dicken, Patrick Joseph Hensley, Natasha Kyprianou · 2018 · Asian journal of urology
49. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
    Dawid Grzegorz Nowak, Ksenya Cohen‐Katsenelson, Kaitlin E. Watrud, Muhan Chen, Grinu Mathew, Vincent D. D’Andrea, Matthew F. Lee, Manojit Mosur Swamynathan, Irene Casanova‐Salas, Megan C. Jibilian et al. · 2019 · The Journal of Cell Biology
50. Mechanistic targets for BPH and prostate cancer–a review
    Abhishek Shah, Aarti Abhishek Shah, Krishnadas Nandakumar, Richard Lobo · 2020 · Reviews on Environmental Health
51. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer
    Rachana Patel, Elspeth A. Brzezińska, Peter Repiščák, Imran Ahmad, Ernest J. Mui, Meiling Gao, Arnaud Blomme, Victoria J. Harle, Ee Hong Tan, Gaurav Malviya et al. · 2019 · Cancer Research
52. Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK–YAP signaling axis
    Yusuke Goto, Toshinori Ando, Hiroki Izumi, Xiaodong Feng, Nadia Arang, Mara Gilardi, Zhiyong Wang, Kazuyo Ando, Jorge Silvio Gutkind · 2020 · Oncogene
53. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer
    Yara Rodríguez, Kenji Unno, Mihai Ioan Truica, Zachary Rockow Chalmers, Young A. Yoo, Rajita J. Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain et al. · 2022 · Cancer Research
54. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function
    Anbarasu Kumaraswamy, Zhi Duan, Diana Lisbeth Flores, Chao Zhang, Archana Sehrawat, Ya‐Mei Hu, Olivia A Swaim, Eva S. Rodansky, William K. Storck, Joshua Agbemefa Kuleape et al. · 2023 · JCI Insight
55. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK
    Jordan S. Shafran, Guillaume P. Andrieu, Balázs Győrffy, Gerald V. Denis · 2019 · Molecular Cancer Research
56. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
    Mark P. Labrecque, Joshi J. Alumkal, Ilsa M. Coleman, Peter S. Nelson, Colm M. Morrissey · 2021 · Endocrine Related Cancer
57. Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo
    Lucas Germain, Camille Lafront, Virginie Paquette, Bertrand Neveu, Jean‐Sébastien Paquette, Frédéric Pouliot, Étienne Audet‐Walsh · 2023 · Nature Reviews Urology
58. IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer
    Deng Wang, Chaping Cheng, Xinyu Chen, Jinming Wang, Kaiyuan Liu, Na Jing, Penghui Xu, Xialian Xi, Yujiao Sun, Zhongzhong Ji et al. · 2023 · Advanced Science
59. Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities
    Parth Anil Desai, Nobuyuki Takahashi, Rajesh Kumar, Samantha Nichols, Justin Malin, Allison L. Hunt, Christopher William Schultz, Yingying Cao, Desiree Tillo, Darryl Nousome et al. · 2024 · Cell Reports Medicine
60. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects
    Sander B. Frank, Peter S. Nelson, Valeri I. Vasioukhin · 2018 · F1000Research
61. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
    Ilsa M. Coleman, Navonil De Sarkar, Colm M. Morrissey, Li Xin, Martine P. Roudier, Erolcan Sayar, Dapei Li, Eva Corey, Michael C. Haffner, Peter S. Nelson · 2022 · Clinical Cancer Research
62. Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
    Nitya V. Sharma, Kathryn L. Pellegrini, Véronique Ouellet, Felipe Giuste, S.S. Ramalingam, Kenneth A. Watanabe, Éloïse Adam-Granger, Lucresse Fossouo, Sungyong You, Michael R. Freeman et al. · 2018 · Cancers
63. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
    Jindan Yu, Galina Gritsina, Wei‐Qiang Gao · 2019 · Asian Journal of Andrology
64. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
    Joshua A. Korsen, Teja M. Kalidindi, Samantha Khitrov, Zachary V. Samuels, Goutam Chakraborty, Julia A. Gutierrez, John T. Poirier, Charles M. Rudin, Yu Chen, Michael J. Morris et al. · 2022 · Journal of Nuclear Medicine
65. Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects
    Mehrdad Hashemi, Sepideh Mirzaei, Maryamsadat Barati, Elahe Sadat Hejazi, Amirabbas Kakavand, Maliheh Entezari, Shokooh Salimimoghadam, Alireza Kalbasi, Mohsen Rashidi, Afshin Taheriazam et al. · 2022 · Life Sciences
66. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response
    Konsta Kukkonen, Sinja Taavitsainen, Laura Huhtala, Joonas Uusi-Mäkelä, Kirsi Johanna Granberg, Matti Nykter, Alfonso Urbanucci · 2021 · Cancers
67. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
    Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian P. Hanratty, Mohamed Adil, Jimmy L. Zhao, Samir Zaidi et al. · 2024 · npj Precision Oncology
68. Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis
    Siyuan Cheng, Lin Li, Yunshin Albert Yeh, Yingli Shi, Omar E. Franco, Eva Corey, Xiuping Yu · 2024 · npj Precision Oncology
69. Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review
    Jing Hu, Bo Han, Jiaoti Huang · 2019 · Archives of Pathology & Laboratory Medicine
70. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer
    Yongyong Yang, Kilia Y. Liu, Qi Liu, Qi Cao · 2021 · Frontiers in Cell and Developmental Biology
71. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth
    Michael D. Nyquist, Lisa S. Ang, Alexandra N. Corella, Ilsa M. Coleman, Michael P. Meers, Anthony J. Christiani, Cordell Pierce, Derek H. Janssens, Hannah E. Meade, Arnab Bose et al. · 2021 · Journal of Clinical Investigation
72. Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
    Yang Li, Shimiao Zhu, Yutong Chen, Qianwang Ma, Duo Kan, Wenyue Yu, Boya Zhang, Xuanrong Chen, Wanqing Wei, Yi Shao et al. · 2023 · Cell Death and Disease
73. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation
    Won Kyung Kim, Alyssa J. Buckley, Donghoon Lee, Alex Hiroto, Christian H. Nenninger, Adam W. Olson, Jinhui Wang, Zhuo Li, Rajeev Vikram, Yao Mawulikplimi Adzavon et al. · 2024 · Nature Communications
74. SRRM4 gene expression correlates with neuroendocrine prostate cancer
    Yinan Li, Qingfu Zhang, Jessica M. Lovnicki, Ruiqi Chen, Ladan Fazli, Yuzhuo Z. Wang, Martin Edwin Gleave, Jiaoti Huang, Xuesen Dong · 2018 · The Prostate
75. Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting
    Andrea K. Miyahira, Adam Sharp, Leigh Ellis, Jennifer Clare Jones, Salma Kaochar, H. Benjamin Larman, David Alan Quigley, Huihui Ye, Jonathan W. Simons, Kenneth J. Pienta et al. · 2019 · The Prostate
76. Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer
    Laura De Vargas Roditi, Andrea Jacobs, Jan H. Rueschoff, Peter Bankhead, Stéphane Chevrier, Hartland Warren Jackson, Thomas Hermanns, Christian Daniel Fankhauser, Cédric Poyet, Felix K.‐H. Chun et al. · 2022 · Cell Reports Medicine
77. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer
    Das, Rajdeep, Sjöström, Martin, Shrestha, Raunak, Yogodzinski, Christopher, Egusa, Emily A., Chesner, Lisa N., Chen, William S., Chou, Jonathan, Dang, Donna K., Swinderman, Jason T. et al. · 2021 · Nature Communications
78. Epigenetic mechanisms underlying prostate cancer radioresistance
    Catarina Macedo‐Silva, Rosaria Benedetti, Fortunato Ciardiello, Salvatore Cappabianca, Cármen Jerónimo, Lucia Altucci · 2021 · Clinical Epigenetics
79. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel
    Estefanía Labanca, Juan Antonio Bizzotto, Pablo Sanchis, Nicolás Anselmino, Jun Yang, Peter D.A. Shepherd, Alejandra Páez, Valeria G. Antico Arciuch, Sofía Lage-Vickers, Anh G. Hoang et al. · 2021 · Oncogene
80. A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer
    Mao-Lin Chen, Ta-Tung Thomas Yuan, Chi-Fen Chuang, Yung-Tsang Huang, I‐Che Chung, Wei‐Ching Huang · 2022 · Molecular Cancer Therapeutics
81. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance
    Jordan E. Vellky, Sean Thomas McSweeney, Emily A. Ricke, William A. Ricke · 2020 · Proceedings of the National Academy of Sciences
82. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
    Michelle Shen, Shiqin Liu, Tanya Ivanova Stoyanova · 2021 · PubMed Central
83. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer
    Kaushal V. Asrani, Alba Fabiola Costa Torres, Juhyung Woo, Thiago Vidotto, Harrison Kwei Tsai, Jun Luo, Eva Corey, Brian P. Hanratty, Ilsa M. Coleman, Srinivasan Yegnasubramanian et al. · 2021 · The Journal of Pathology
84. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
    Wanting Han, Mingyu Liu, Dong Gwan Han, Anthia A. Toure, Muqing Li, Anna Besschetnova, Zifeng Wang, Susan C. Patalano, Jill A. Macoska, Hung‐Ming Lam et al. · 2022 · Molecular Therapy
85. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers
    Daniel H.F. Hui, Kevin J. Tam, Ivy Z. F. Jiao, Christopher John Ong · 2019 · International Journal of Molecular Sciences
86. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
    Landon Carter Brown, Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Zelig Szmulewitz, Daniel Costin Danila, Ethan S. Barnett et al. · 2021 · Clinical Cancer Research
87. Personalization of prostate cancer therapy through phosphoproteomics
    Wei Yang, Michael R. Freeman, Natasha Kyprianou · 2018 · Nature Reviews Urology
88. Cancer‐driven IgG promotes the development of prostate cancer though the SOX2‐CIgG pathway
    Caipeng Qin, Zhengzuo Sheng, Xinmei Huang, Jingshu Tang, Yang Liu, Tao Xu, Xiaoyan Qiu · 2020 · The Prostate
89. ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
    Eric H. Kim, Dengfeng Cao, Nupam P. Mahajan, Gerald L. Andriole, Kiran N. Mahajan · 2020 · NAR Cancer
90. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
    William K. Storck, Allison Marie May, Thomas Christopher Westbrook, Zhi Duan, Colm M. Morrissey, Joel A. Yates, Joshi J. Alumkal · 2022 · Frontiers in Endocrinology
91. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression
    Raunak Shrestha, Lisa N. Chesner, Meng Zhang, Stanley Zhou, Adam Foye, Arian Lundberg, Alana S. Weinstein, Martin Sjöström, Xiaolin Zhu, Thaidy Moreno-Rodriguez et al. · 2024 · Cancer Research
92. Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
    Cong Wang, Ziying Liu, Yuepeng Ke, Fen Wang · 2019 · Frontiers in Genetics
93. The molecular function of kallikrein‐related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer
    Thomas Kryza, Nathalie Bock, Scott Lovell, Anja Rockstroh, Melanie Lehman, Adam Lesner, Janaththani Panchadsaram, Lakmali Munasinghage Silva, Srilakshmi Srinivasan, Cameron Edward Snell et al. · 2019 · Molecular Oncology
94. Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer
    Mark D. Long, Justine J. Jacobi, Prashant Kumar Singh, Gerard Llimos, Sajad A. Wani, Aryn M. Rowsam, Spencer R. Rosario, Marlous Hoogstraat, Simon Linder, Jason S. Kirk et al. · 2021 · Cell Reports
95. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer
    Andrej Zivanovic, Jeffrey T. Miller, Sarah A. Munro, Todd Philip Knutson, Yingming Li, Courtney N. Passow, Pijus Simonaitis, Molly Lynch, LeAnn Oseth, Shuang George Zhao et al. · 2023 · NAR Cancer
96. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
    Nicolás Anselmino, Estefanía Labanca, Peter D.A. Shepherd, Jiabin Dong, Jun Yang, Xiaofei Song, Subhiksha Nandakumar, Ritika Kundra, Cindy J. Lee, Nikolaus D. Schultz et al. · 2024 · Clinical Cancer Research
97. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
    Michael C. Haffner, Michael J. Morris, Chien‐Kuang Cornelia Ding, Erolcan Sayar, Rohit Mehra, Brian D. Robinson, Lawrence D. True, Martin Edwin Gleave, Tamara Levin Lotan, Rahul Raj Aggarwal et al. · 2024 · Clinical Cancer Research
98. Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
    Rachana Patel, Janis Fleming, Ernest J. Mui, Carolyn J. Loveridge, Peter Repiščák, Arnaud Blomme, Victoria J. Harle, Mark J. Salji, Imran Ahmad, Katy Teo et al. · 2018 · EMBO Molecular Medicine
99. Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer
    Yung-Wei Lin, Yu‐Ching Wen, Chih‐Ying Chu, Min‐Che Tung, Yi‐Chieh Yang, Kuo‐Tai Hua, Ke‐Fan Pan, Michael Hsiao, Wei-Jiunn Lee, Ming‐Hsien Chien · 2020 · Cell Death and Disease
100. Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
     Timon A. Bloedjes, Guus de Wilde, Jeroen E. J. Guikema · 2021 · Cancers